OBJECTIVES: To assess clinical characteristics of RA patients considered biosimilar-infliximab-suitable (when it becomes available) by their physicians, in comparison to those who were not considered infliximab-biosimilar-suitable in EU. METHODS: A medical chart-review study of RA patients was conducted among physicians (primarily rheumatologists) in hospitals/private practices in UK/France/Germany/Italy/Spain (5EU) to collect de-identified data on patient diagnosis, treatment patterns/dynamics and patient symptomatology/disease status; physicians identified whether patient was biosimilar-infliximab-suitable (yes/no), and if yes, rated how likely would they prescribe biosimilar-infliximab to them when the product becomes available. Physicians were screened for practice-duration and patient-volume and recruited from a large panel to be geographically representative. Consecutive patients currently on (or discontinued within past-3mo) biologic visiting each center/practice during the screening period were selected for chart abstraction; analysis compared biosimilar-infliximab-suitable to those who were not (per physician judgment), excluding those who previously failed infliximab. RESULTS: CONCLUSIONS: Patients considered infliximab-biosimilar-suitable (per clinical judgment) had been in care for relatively shorter period, had higher disease severity and a lower percentage of them used steroids. Physicians were also not readily prepared to prescribe the biosimilar to all infliximab-biosimilar-suitable patients. Further scrutiny is warranted to understand the drivers behind physician perception of biosimilar-infliximab-suitability.